Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)



Status:Archived
Conditions:Lung Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:July 2006
End Date:June 2011

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC)


To determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.



We found this trial at
2
sites
Hematology Oncology Associates of the Quad Cities
1351 Kimberly Rd
Bettendorf, Iowa 52722
(563) 355-7733
Hematology Oncology Associates of the Quad Cities
?
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Clinical Trial Facility
Austin, Texas
?
mi
from
Austin, TX
Click here to add this to my saved trials